Ornithine aspartate granule — Competitive Intelligence Brief

Ornithine aspartate granule (Ornithine aspartate granule) competitive landscape: 2 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Ammonia-lowering agent. Area: Hepatology / Gastroenterology.

marketed Ammonia-lowering agent Hepatology / Gastroenterology Small molecule

Target snapshot

Ornithine aspartate granule (Ornithine aspartate granule) — Xinhua Hospital, Shanghai Jiao Tong University School of Medicine. Ornithine aspartate reduces ammonia levels by promoting its incorporation into urea and glutamine synthesis, thereby improving hepatic encephalopathy symptoms.

Comparator set (2 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Ornithine aspartate granule TARGET	Ornithine aspartate granule	Xinhua Hospital, Shanghai Jiao Tong University School of Medicine	marketed	Ammonia-lowering agent
L-ornithine-L-aspartate plus latulose	L-ornithine-L-aspartate plus latulose	Qurratul Ain Jamil	marketed	Ammonia-lowering agent combination
L-ornithine L-aspartate	L-ornithine L-aspartate	Medical University of Graz	marketed	Ammonia-lowering agent	Urea cycle enzymes (ornithine transcarbamylase, carbamoyl phosphate synthetase); glutamine synthetase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Ammonia-lowering agent class)

1. Medical University of Graz · 1 drug in this class
2. Xinhua Hospital, Shanghai Jiao Tong University School of Medicine · 1 drug in this class